Advertisement

Documenta Ophthalmologica

, Volume 127, Issue 3, pp 177–190 | Cite as

Role of visual evoked potentials in the assessment and management of optic pathway gliomas in children

  • C. Van MierloEmail author
  • W. Spileers
  • E. Legius
  • I. Casteels
  • C. Cassiman
Review Article

Abstract

Objective

The aim of this study is to investigate the role of pattern reversal visual evoked potentials (pVEPs) in the screening and monitoring of optic pathway gliomas (OPGs) in children with and without neurofibromatosis type 1.

Methods

A review of the English literature published between 1980 and 2012 was performed, with comparison of results of retro- and prospective studies.

Results

Pattern reversal VEPs have a high sensitivity (85.7–100 %) for the diagnosis of OPGs, moreover they are safe and cost-effective. Conversely, they have a low specificity (43–83 %) and are not widely available. Besides, pattern reversal VEP results can be unreliable in young children, because of the need for a good cooperation. The studies that were analyzed have drawbacks, including the small sample size, the retrospective design, the differences in gold standard for diagnosis, the different interpretation of small changes in VEP results and the lack of control groups.

Conclusion

There is still debate about the gold standard for the screening and follow-up of OPGs. The added value of pVEPs to the ophthalmic examination is controversial. Randomized controlled trials or prospective multicentre studies are necessary to assess with sufficient accuracy the sensitivity and specificity of pattern reversal VEPs in the screening for OPGs and its follow-up.

Keywords

Optic pathway glioma Neurofibromatosis type 1 Visual evoked potentials Children 

Notes

Conflict of interest

None.

References

  1. 1.
    Listernick R, Charrow J, Gutmann DH (1999) Intracranial gliomas in neurofibromatosis type 1. Am J Med Genet 89:38–44CrossRefPubMedGoogle Scholar
  2. 2.
    Ng Y, North KN (2001) Visual-evoked potentials in the assessment of optic gliomas. Pediatr Neurol 24:44–48CrossRefPubMedGoogle Scholar
  3. 3.
    North K, Cochineas C, Tang E, Fagan E (1994) Optic gliomas in neurofibromatosis type 1: role of visual evoked potentials. Pediatr Neurol 10:117–123CrossRefPubMedGoogle Scholar
  4. 4.
    Thiagalingam S, Flaherty M, Billson F, North K (2004) Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Ophthalmology 111:568–577CrossRefPubMedGoogle Scholar
  5. 5.
    Wolsey DH, Larson SA, Creel D, Hoffman R (2006) Can screening for optic nerve gliomas in patients with neurofibromatosis type I be performed with visual-evoked potential testing? J AAPOS 10:307–311CrossRefPubMedGoogle Scholar
  6. 6.
    Avery RA, Fisher MJ, Liu GT (2011) Optic pathway gliomas. J Neuroophthalmol 31:269–278CrossRefPubMedGoogle Scholar
  7. 7.
    Binning MJ, Liu JK, Kestle JR, Brockmeyer DL, Walker ML (2007) Optic pathway gliomas: a review. Neurosurg Focus 23:E2CrossRefPubMedGoogle Scholar
  8. 8.
    Lee AG (2007) Neuroophthalmological management of optic pathway gliomas. Neurosurg Focus 23:E1CrossRefPubMedGoogle Scholar
  9. 9.
    Shapey J, Danesh-Meyer HV, Kaye AH (2011) Diagnosis and management of optic nerve glioma. J Clin Neurosci 18:1585–1591CrossRefPubMedGoogle Scholar
  10. 10.
    Boyd KP, Korf BR, Theos A (2009) Neurofibromatosis type 1. J Am Acad Dermatol 61:1–14CrossRefPubMedGoogle Scholar
  11. 11.
    Listernick R, Ferner RE, Liu GT, Gutmann DH (2007) Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 61:189–198CrossRefPubMedGoogle Scholar
  12. 12.
    Daginakatte GC, Gutmann DH (2007) Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Hum Mol Genet 16:1098–1112CrossRefPubMedGoogle Scholar
  13. 13.
    Sharif S, Upadhyaya M, Ferner R, Majouni E, Shenton A, Baser M, Thakker N, Evans DG (2011) A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations. J Med Genet 48:256–260CrossRefPubMedGoogle Scholar
  14. 14.
    Kornreich L, Blaser S, Schwarz M, Shuper A, Vishne TH, Cohen IJ, Faingold R, Michovitz S, Koplewitz B, Horev G (2001) Optic pathway glioma: correlation of imaging findings with the presence of neurofibromatiosis. Am J Neuroradiol 22:1963–1969PubMedGoogle Scholar
  15. 15.
    Shamji MF, Benoit BG (2007) Syndromic and sporadic pediatric optic pathway gliomas: review of clinical and histopathological differences and treatment implications. Neurosurg Focus 23:E3CrossRefPubMedGoogle Scholar
  16. 16.
    Opocher E, Kremer LC, Da Dalt L, van de Wetering MD, Viscardi E, Caron HN, Perilongo G (2006) Prognostic factors for progression of childhood optic pathway glioma: a systematic review. Eur J Cancer 42:1807–1816CrossRefPubMedGoogle Scholar
  17. 17.
    Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, Packer RJ, Tabori U, Hoffman RO, Ardern-Holmes SL, Hummel TR, Hargrave DR, Bouffet E, Charrow J, Bilaniuk LT, Balcer LJ, Liu GT (2012) Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a retrospective analysis. Neuro Oncol 14:790–797CrossRefPubMedGoogle Scholar
  18. 18.
    Lenassi E, Likar K, Stirn-Kranjc B, Brecelj J (2008) VEP maturation and visual acuity in infants and preschool children. Doc Ophthalmol 117:111–120CrossRefPubMedGoogle Scholar
  19. 19.
    Odom JV, Bach M, Brigell M, Holder GE, McCulloch DL, Tormens AP, Vaegan (2010) ISCEV standard for clinical visual evoked potentials (2009 update). Doc Ophthalmol 120:111–119Google Scholar
  20. 20.
    Tobimatsu S, Celesia GG (2006) Studies of human visual pathophysiology with visual evoked potentials. Clin Neurophysiol 117:1414–1433CrossRefPubMedGoogle Scholar
  21. 21.
    Halliday AM, Mushin J (1980) The visual evoked potential in neuroophthalmology. Int Ophthalmol Clin 20:155–183CrossRefPubMedGoogle Scholar
  22. 22.
    Taylor MJ, McCulloch DL (1992) Visual evoked potentials in infants and children. J Clin Neurophysiol 9:357–372CrossRefPubMedGoogle Scholar
  23. 23.
    Kriss A, Russell-Eggitt I (1992) Electrophysiological assessment of visual pathway function in infants. Eye 6:145–153CrossRefPubMedGoogle Scholar
  24. 24.
    Brecelj J, Strucl M, Zidar I, Tekavcic-Pompe M (2002) Pattern ERG and VEP maturation in schoolchildren. Clin Neurophysiol 113:1764–1770CrossRefPubMedGoogle Scholar
  25. 25.
    Cohen ME, Duffner PK (1983) Visual-evoked responses in children with optic gliomas, with and without neurofibromatosis. Child Brain 10:99–111Google Scholar
  26. 26.
    Groswasser Z, Kriss A, Halliday AM, McDonald WI (1985) Pattern- and flash-evoked potentials in the assessment and management of optic nerve gliomas. J Neurol Neurosurg Psychiatry 48:1125–1134CrossRefPubMedGoogle Scholar
  27. 27.
    Lund AM, Skovby F (1991) Optic gliomas in children with neurofibromatosis type 1. Eur J Pediatr 150:835–838CrossRefPubMedGoogle Scholar
  28. 28.
    Wenzel D, Brandl U, Beck JD, Cedzich C, Albert F (1988) Visual evoked potentials in tumors from orbita to occipital lobe in childhood. Neurosurg Rev 11:279–286Google Scholar
  29. 29.
    Jabbari B, Maitland CG, Morris LM, Morales J, Gunderson CH (1985) The value of visual evoked potential as a screening test in neurofibromatosis. Arch Neurol 42:1072–1074CrossRefPubMedGoogle Scholar
  30. 30.
    Siatkowski RM (2006) VEP testing and visual pathway gliomas: not quite ready for prime time. J AAPOS 10:293–295CrossRefPubMedGoogle Scholar
  31. 31.
    Kelly JP, Leary S, Khanna P, Weiss AH (2012) Longitudinal measures of visual function, tumor volume, and prediction of visual outcomes after treatment of optic pathway gliomas. Ophthalmology 119:1231–1237CrossRefPubMedGoogle Scholar
  32. 32.
    Ammendola A, Ciccone G, Ammendola E (2006) Utility of multimodal evoked potentials study in neurofibromatosis type 1 of childhood. Pediatr Neurol 34:276–280CrossRefPubMedGoogle Scholar
  33. 33.
    Yerdelen D, Koc F, Durdu M, Karakas M (2011) Electrophysiological findings in neurofibromatosis type 1. J Neurol Sci 306:42–48CrossRefPubMedGoogle Scholar
  34. 34.
    Rossi LN, Pastorino G, Scotti G, Gazocchi M, Maninetti MM, Zanolini C, Chiodi A (1994) Early diagnosis of optic glioma in children with neurofibromatosis type 1. Child Nerv Syst 10:426–429CrossRefGoogle Scholar
  35. 35.
    Iannaccone A, McCluney RA, Brewer VR, Spiegel PH, Taylor JS, Kerr NC, Pivnick EK (2002) Visual evoked potentials in children with neurofibromatosis type 1. Doc Ophthalmol 105:63–81CrossRefPubMedGoogle Scholar
  36. 36.
    Moradi P, Robson AG, Rose GE, Holder GE (2008) Electrophysiological monitoring in a patient with an optic nerve glioma. Doc Ophthalmol 117:171–174CrossRefPubMedGoogle Scholar
  37. 37.
    Brecelj J, Stim-Kranjc B, Skrbec M (2000) Visual electrophysiology in children with tumours affecting the visual pathway. Case reports. Doc Ophthalmol 101:125–154CrossRefPubMedGoogle Scholar
  38. 38.
    Holder GE, Gale RP, Acheson JF, Robson AG (2009) Electrodiagnostic assessment in optic nerve disease. Curr Opin Neurol 22:3–10CrossRefPubMedGoogle Scholar
  39. 39.
    Chang BC, Mirabella G, Yagev R, Banh M, Mezer E, Parkin PC, Westall CA, Buncic JR (2007) Screening and diagnosis of optic pathway gliomas in children with neurofibromatosis type 1 by using sweep visual evoked potentials. Invest Ophthalmol Vis Sci 48:2895–2902CrossRefPubMedGoogle Scholar
  40. 40.
    Trisciuzzi MT, Riccardi R, Piccardi M, Iarossi G, Buzzonetti L, Dickmann A, Colosimo CJ, Ruggiero A, Di Rocco C, Falsini B (2004) A fast visual evoked potential method for functional assessment and follow-up of childhood optic gliomas. Clin Neurophysiol 115:217–226CrossRefPubMedGoogle Scholar
  41. 41.
    Falsini B, Ziccardi L, Lazzareschi I, Ruggiero A, Placentino L, Dickmann A, Liotti L, Piccardi M, Balestrazzi E, Colosimo C, Di Rocco C, Riccardi R (2008) Longitudinal assessment of childhood optic gliomas: relationship between flicker visual evoked potentials and magnetic resonance imaging findings. J Neurooncol 88:87–96CrossRefPubMedGoogle Scholar
  42. 42.
    Pilling RF, Taylor RH (2010) Screening children with nF1-no. Eye 24:1432–1434CrossRefPubMedGoogle Scholar
  43. 43.
    Chang L, El-Dairi MA, Frempong TA, Burner EL, Bhatti MT, Young TL, Leigh F (2010) Optical coherence tomography in the evaluation of neurofibromatosis type-1 subjects with optic pathway gliomas. J AAPOS 14:511–517CrossRefPubMedGoogle Scholar
  44. 44.
    Avery RA, Liu GT, Fisher MJ, Quinn GE, Belasco JB, Phillips PC, Maguire MG, Balcer LJ (2011) Retinal nerve fiber layer thickness in children with optic pathway gliomas. Am J Ophthalmol 151:542–549CrossRefPubMedGoogle Scholar
  45. 45.
    Segal L, Darvish-Zargar M, Dilenge ME, Ortenberg J, Polomeno RC (2010) Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients. J AAPOS 14:155–158CrossRefPubMedGoogle Scholar
  46. 46.
    Blazo MA, Lewis RA, Chintagumpala MM, Frazier M, McCluggage C, Plon SE (2004) Outcomes of systematic screening for optic pathway tumors in children with neurofibromatosis type 1. Am J Med Genet A 127:224–229CrossRefGoogle Scholar
  47. 47.
    Dhermain FG, Hau P, Lanfermann H, Jacobs AH, Van Den Bent MJ (2010) Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol 9:906–920CrossRefPubMedGoogle Scholar
  48. 48.
    Jost SC, Ackerman JW, Garbow JR, Manwaring LP, Gutmann DH, McKinstry RC (2008) Diffusion-weighted and dynamic contrast-enhanced imaging as markers of clinical behavior in children with optic pathway glioma. Pediatr Radiol 38:1293–1299CrossRefPubMedGoogle Scholar
  49. 49.
    Parsa CF (2012) Why visual function does not correlate with optic glioma size or growth. Arch Ophthalmol 130:521–522CrossRefPubMedGoogle Scholar
  50. 50.
    Simmons I, Gogi D (2010) Screening children with NF1-yes. Eye 24:1429–1431CrossRefPubMedGoogle Scholar
  51. 51.
    Liu GT, Malloy P, Needle M, Phillips P (1995) Optic gliomas in neurofibromatosis type 1: role of visual evoked potentials. Pediatr Neurol 12:89–90CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • C. Van Mierlo
    • 1
    Email author
  • W. Spileers
    • 1
  • E. Legius
    • 2
  • I. Casteels
    • 1
  • C. Cassiman
    • 1
  1. 1.Department of OphthalmologyUniversity Hospitals of LeuvenLeuvenBelgium
  2. 2.Centre for Human GeneticsUniversity Hospitals LeuvenLeuvenBelgium

Personalised recommendations